Nivolumab Safer, More Effective Than Chemo for Advanced Melanoma
Nivolumab led to a greater proportion of patients with advanced melanoma achieving an objective response and with fewer adverse events.
Diagnosis & Disease Information
Vitiligo-Like Depigmentation During Immunotherapy Associated with Improved Survival
Although vitiligo-like depigmentation occurs only in patients with melanoma treated with immunotherapy, there is an evident survival benefit.
QTc Not Prolonged by Onartuzumab Plus Paclitaxel With or Without Bevacizumab
Onartuzumab with weekly paclitaxel with or without bevacizumab does not prolong the corrected QT (QTc) interval.
Capecitabine Not Effective as First-line Therapy When Added to Taxanes and Bevacizumab
Biology of metastatic breast cancer has become more aggressive, resulting in resistance to a number of treatment options.
Recommended Dose of Cixutumumab for Children with Recurrent Solid Tumors Determined
Cixutumumab is a monoclonal antibody that has potent anti-tumor activity in a variety of cell-lines and xenografts.
Cetuximab Plus PX-866 Not Effective for Recurrent, Metastatic Head and Neck Cancer
Addition of PX-866 to cetuximab did not provide clinical benefit to relapsed or metastatic head and neck squamous cell carcinoma.
For Non-Small Cell Lung Cancer, Bevacizumab Plus Chemotherapy Not Effective
Bevacizumab, paclitaxel, and carboplatin did not achieve the prespecified objective response rate goal for non-small cell lung cancer.
Dose-Adjusted R-EPOCH Provides Long-Term Benefit for High-Risk Large B-Cell Lymphoma
DA-EPOCH-R showed good long-term benefit and was well tolerated in high-risk large B cell lymphoma.
Phase I DNA Immunotherapy Trial Initiated in Adults with Breast, Lung, and Pancreatic Cancer
High levels of hTERT (human telomerase reverse transcriptase) expression are found in 85% of human cancers, and is therefore a significant target for treatment.
For Lymphoma Patients Receiving R-CHOP, Entecavir More Effective for HBV-Related Hepatitis Prophylaxis
Risk of hepatitis B virus (HBV) related hepatitis and HBV reactivation is lower with entecavir and lamivudine in lymphoma.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...